Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Gilead Sciences |
---|---|
Information provided by: | Gilead Sciences |
ClinicalTrials.gov Identifier: | NCT00768300 |
The ARTEMIS study is for people who have been diagnosed with IPF in the last 3 years and are between 40-80 years of age. People who have been diagnosed early in the disease may be more responsive to treatment. This is a randomized study (which means the participants will be selected by chance (like flipping a coin) to receive one of two treatments (ambrisentan or placebo). This is a double-blind study which means participants and their study doctor won't know what treatment they are assigned to receive. Participants will have 2 out of 3 chances to receive ambrisentan, or 1 out of 3 chances to receive placebo (which is a tablet that looks like the active medicine but contains no active medicine)Taking part in the study could be up to 3 years depending on how long it takes to enroll and observe study events. After randomization, visits take place every 3 months. Laboratory visits occur every month.
Condition | Intervention | Phase |
---|---|---|
Idiopathic Pulmonary Fibrosis |
Drug: ambrisentan or sugar pill |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | ARTEMIS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF) |
Estimated Enrollment: | 600 |
Study Start Date: | December 2008 |
Estimated Study Completion Date: | December 2012 |
Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1 Ambrisentan: Active Comparator
Subjects will be randomized in a 2:1 ratio to receive Ambrisentan
|
Drug: ambrisentan or sugar pill
Ambrisentan 5mg or 10 mg tablet, or sugar pill (placebo) taken once a day, by mouth for the duration of the trial.
|
2 Placebo: Placebo Comparator
Subjects will be randomized in a 2:1 ratio to receive active drug versus sugar pill (placebo.
|
Drug: ambrisentan or sugar pill
Ambrisentan 5mg or 10 mg tablet, or sugar pill (placebo) taken once a day, by mouth for the duration of the trial.
|
Ages Eligible for Study: | 40 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Crystal Green | AMS-IPF@gilead.com |
Study Chair: | Ganesh Raghu, MD | University of Washington, Div. of Pulmonary and Critical Care Medicine Chair |
Responsible Party: | GSI ( Brent Appleton, MD ) |
Study ID Numbers: | GS-US-231-0101 |
Study First Received: | October 7, 2008 |
Last Updated: | December 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00768300 |
Health Authority: | United States: Food and Drug Administration |
idiopathic pulmonary fibrosis interstitial lung disease ambrisentan |
Lung Diseases, Interstitial Respiratory Tract Diseases Fibrosis |
Hamman-Rich syndrome Lung Diseases Pulmonary Fibrosis |
Pathologic Processes |